Clinical trials: Colorectal Diseases
Colo-rectal Cancer
Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC)
The FIND-CRC study is a prospective collection of samples and data from participants who are at average risk of developing colorectal cancer (CRC).
- Trial name
- FIND-CRC (NCT07046585)
- Where
- United States
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Natera, Inc.
Rectal Cancer
A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer
The purpose of this study is to determine the pathological complete tumor response rate.
- Trial name
- NCT02694718
- Testing
- Capecitabine, Oxaliplatin
- Where
- 6 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Colon Neoplasms
AI-Assisted Microbiome Analysis for Evaluating the Efficacy of MPRO3 and Gut Environmental Changes in Colon Cancer Surgery Patients
The goal of this clinical trial is to evaluate the effects of MPRO3(probiotics mixture) supplementation on surgical outcomes and gut health in patients undergoing surgery for colon cancer.The main question is whether MPRO3…
- Trial name
- AI-MPRO3 (NCT07792980)
- Testing
- MPRO3
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- hy Co., LTD.
Left-sided Colorectal Resection : Diverticular Diseases, Left-sided Colorectal Resection : Colonic Neoplasms
InTRaoperative Imaging DEvice Based on endogeNous opTical Properties to Evaluate Bowel Oxygenation in Colorectal Resections
The objective of the study is to assess the safety and technical feasibility of a new imaging system, used during colorectal resection surgery, named Trident in version 1.0, which could be used by the surgeon during colorectal…
- Conditions
- Left-sided Colorectal Resection : Diverticular Diseases, Left-sided Colorectal Resection : Colonic Neoplasms, Left-sided Colorectal Resection : Rectal Neoplasms
- Trial name
- TRIDENT (NCT05973227)
- Testing
- use of the TRIDENT system
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Intuitive Surgical
Unresectable Metastatic Colorectal Cancer
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given in combination with…
- Trial name
- NCT06107413
- Testing
- ABBV-400, Bevacizumab, Folinic Acid
- Where
- 64 sites in United States, Belgium and 6 more
- Volunteers
- 280 people
- Sponsor
- AbbVie
Colorectal Cancer
A Study of Picoplatin in Colorectal Cancer
Colorectal cancer is a type of cancer that begins in the large intestine (colon) or the rectum (end of the colon). Several drugs are often given in combination to treat colorectal cancer.
- Trial name
- NCT00478946
- Testing
- (FOLPI) Picoplatin with 5-FU and Leucovorin, FOLPI, FOLFOX
- Where
- 16 sites in Russia
- Volunteers
- 43 people
- Sponsor
- Poniard Pharmaceuticals
Metastatic Colorectal Cancer
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given…
- Trial name
- AndroMETa-CRC (NCT06820463)
- Testing
- Telisotuzumab Adizutecan, Fluorouracil, Oxaliplatin
- Where
- 82 sites in United States, Australia and 13 more
- Volunteers
- 390 people
- Sponsor
- AbbVie
Colorectal Cancer
Study of S-1 Plus LV for Untreated Metastatic Colorectal Cancer
This is a multicenter study designed to evaluate the response rate of S-1 plus Leucovorin (1 week on and 1 week off) as first -line treatment for patients with metastatic colorectal cancer.
- Trial name
- NCT00891332
- Testing
- S-1 plus LV (The combination therapy of S-1 and Leucovorin)
- Where
- 6 sites in China, Japan
- Volunteers
- 73 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Metastatic Colorectal Adenocarcinoma
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer
This trial studies how well the drug tucatinib works when given with trastuzumab and when given by itself. The participants in this trial have HER2-positive (HER2+) metastatic colorectal cancer (mCRC).
- Trial name
- NCT03043313
- Testing
- Trastuzumab, Tucatinib
- Where
- 56 sites in United States, Belgium and 3 more
- Volunteers
- 117 people
- Sponsor
- Seagen Inc.
Colorectal Cancer
Effect of Oral Administration of Methylene Blue MMX Tablets on Double Stranded DNA
Single Centre, open label assignment phase II clinical study. To evaluate the effect of oral 200mg Methylene Blue tablets (administered 8x25mg) prior to endoscopy on double stranded DNA breaks in colonic biopsy samples assessed…
- Trial name
- NCT02295774
- Testing
- Methylene Blue MMX tablets
- Where
- Italy
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Cosmo Technologies Ltd
Colorectal Carcinoma, Metastases
Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases
This study will be conducted in subjects with refractory colorectal carcinoma with unresectable liver metastases. The purposes of the study are: to evaluate the safety and any harmful effects of an intravenous injection of…
- Trial name
- NCT00107861
- Testing
- Ad.hIFN-β (BG00001, IDEC-201)
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Biogen
BRAF V600E-mutant Metastatic Colorectal Cancer
Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer
The purpose of this study is to evaluate the efficacy and safety of the combination of study drugs encorafenib, binimetinib and cetuximab in patients who have BRAF V600 mutant metastatic colorectal cancer and have not received…
- Trial name
- ANCHOR-CRC (NCT03693170)
- Testing
- encorafenib, Binimetinib, Cetuximab
- Where
- 45 sites in United States, Austria and 7 more
- Volunteers
- 95 people
- Sponsor
- Pierre Fabre Medicament
Non-small Cell Lung Cancer, Head and Neck Cancer
A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors
This is a phase 1, multi-center, dose escalation, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of JAB-3068 in adult patients with advanced solid.
- Conditions
- Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
- Trial name
- NCT03518554
- Testing
- JAB-3068
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Colorectal Cancer
Prevention of Irinotecan Induced Diarrhea by Probiotics
Irinotecan is one of key drug used in the treatment of colorectal cancer. The incidence of irinotecan induced diarrhea varies between 60-90%, with severe diarrhea in 20-40%.
- Trial name
- NCT01410955
- Testing
- Probiotic formula
- Where
- 6 sites in Slovakia
- Volunteers
- 46 people
- Sponsor
- Monsea Ltd.
Colon Cancer, Organoids
Cetuximab Sensitivity Correlation Between Patient-Derived Organoids and Clinical Response in Colon Cancer Patients.
Eighty patients with RAS/RAF wild-type metastatic right colon cancer will be enrolled and undergo a fresh biopsy of tumor lesion before the standard treatment of chemotherapy.
- Conditions
- Colon Cancer, Organoids, Metastatic Cancer
- Trial name
- NCT04906733
- Testing
- Tumor biopsy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- D1 Medical Technology (Shanghai) Co., Ltd, China
Breast Cancer, Colorectal Cancer
Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples
The study is intended to collect specimens to support the application of genome analysis technologies, including large-scale genome sequencing.
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
- Trial name
- GBCPRT0008 (NCT01792882)
- Where
- United States
- Sponsor
- Global BioClinical
Breast Cancer, Head and Neck Cancer
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
This study evaluated the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study was conducted in patients with several types of refractory cancers including those at the surface of the…
- Conditions
- Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma
- Trial name
- IT-01 (NCT03058289)
- Testing
- INT230-6, anti-PD-1 antibody, anti-CTLA-4 antibody
- Where
- 8 sites in United States, Canada
- Volunteers
- 111 people
- Sponsor
- Intensity Therapeutics, Inc.
Colorectal Cancer, Adenoma
Comparing Detection of Standard Colonoscopy, CAD-EYE and Combined CAD-EYE and G-EYE® Aided Colonoscopy
The purpose of this study is to compare the additional diagnostic yield over Standard Colonoscopy (i.e., the adenoma miss-rate reduction) obtained by performing CADEYE and G-EYE® aided colonoscopy, vs.
- Trial name
- NCT05237310
- Testing
- Standard Colonoscopy, G-EYE Colonoscopy, CAD-EYE
- Where
- Germany
- Volunteers
- 372 people, healthy volunteers welcome
- Sponsor
- Smart Medical Systems Ltd.
Colorectal Cancer
Safety and Immune Response to FMPV-1
This is a single centre, open-label, non-randomized, Phase I study assessing safety and immune response of FMPV-1 in healthy male subjects.
- Trial name
- NCT05238558
- Testing
- FMPV-1, GM-CSF (as adjuvant)
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Hubro Therapeutics AS
Colorectal Cancer, Melanoma
BESPOKE Study of ctDNA Guided Immunotherapy
This is a prospective data collection study of patients with advanced solid tumors who will receive standard of care immunotherapy (IO) and will be monitored with SIGNATERA™ testing.
- Conditions
- Colorectal Cancer, Melanoma, Non-small Cell Lung Cancer
- Trial name
- NCT04761783
- Where
- United States
- Volunteers
- 290 people
- Sponsor
- Natera, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.